AT9283CAS号: 896466-04-9分子式: C19H23N7O2分子量: 381.43描述纯度储存/保存方法可溶性/溶解性靶点In vitro(体外研究)In vivo(体内研究)参考文献
产品描述 | |
描述 |
AT9283是一种有效的JAK2/3抑制剂,IC50为1.2 nM/1.1 nM;对Aurora A/B, Abl(T315I)也有效。在体外, AT9283有效抑制多种激酶,包括 Aurora A, Aurora B, JAK3, JAK2和 Abl,IC50分别为3 nM, 3 nM, 1.1 nM, 1.2 nM 和 4 nM。AT9283 作用于HCT116 细胞,通过抑制Aurora B 激酶活性,产生明显的多倍体表现型,IC50为30 nM。而且, AT9283也有效抑制HCT116形成集落。 |
纯度 |
>98%
|
储存/保存方法 |
Store at -20℃ for one year(Powder);Store at 2-4℃ for two weeks;Store at -20℃ for six months after dissolution.
|
基本信息 | |
可溶性/溶解性 |
Ethanol :36 mg/mL (94.4 mM)
DMSO :71 mg/mL (186.1 mM) |
生物活性 | |
靶点 |
JAK3 ,JAK2 ,Aurora A ,Aurora B ,Abl1 (T315I)
|
In vitro(体外研究) |
AT9283 leads to a clear polyploid phenotype by inhibiting the activity of Aurora B kinase in HCT116 cells with IC50 of 30 nM. Furthermore, AT9283 also produces the potent inhibition on HCT116 colony formation.
|
In vivo(体内研究) |
In HCT116 human colon carcinoma xenograft bearing mice, AT9283 treatment (15 mg/kg and 20 mg/kg) for 16 days results in a significant tumor growth inhibition of 67% and 76%, respectively. In addition, AT9283 also exhibits a significantly longer half-life in tumors(2.5 hours) compared with plasma (0.5 hour) and modest oral bioavailability in mice (Fp.o. = 24%).
|
参考文献 | |
参考文献 |
A phase I dose escalation study of AT9283, a small molecule inhibitor of aurora kinases, in patients with advanced solid malignancies.
Arkenauet al. Ann Oncol. 2012 May;23(5):1307-13. PMID: 分子结构图
|